The organ transplant technology firm reported record Q2 2026 revenue of $190 million and outlined long-term growth targets.
TransMedics set a 2026 revenue outlook of $737 million to $757 million, reflecting confidence in its organ transplant platform. The company also aims to facilitate 30,000 transplants annually by 2032, up from current volumes.
Q2 2026 marked a record quarter, with revenue reaching approximately $190 million. Management highlighted strong case volume growth and the expansion of its Organ Care System (OCS) as key drivers.
The company positioned itself as a vertically integrated leader in transplant technology, emphasizing scalability and innovation in its long-term strategy.